Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.2
2.8
Journals
Genes
Special Issues
Multifaceted Implications of Non-Coding RNAs in Cancer: From Biomarker Discovery...
share announcement

Multifaceted Implications of Non-Coding RNAs in Cancer: From Biomarker Discovery to Therapeutic Target

A special issue of Genes (ISSN 2073-4425). This special issue belongs to the section "RNA".

Deadline for manuscript submissions: 20 June 2025 | Viewed by 2165

Special Issue Editors

Dr. Vikas Yadav

E-Mail Website
Guest Editor
Department of Translational Medicine, Clinical Research Centre, Lund University, Skåne University Hospital, 20049 Malmö, Sweden
Interests: apoptosis; cancer; drug repositioning; metastasis; non-coding RNA; peptide based drug discovery; translational research; WNT signaling
Special Issues, Collections and Topics in MDPI journals
Dr. Hardeep Singh Tuli

E-Mail Website
Guest Editor
Department of Biotechnology, Maharishi Markandeshwar (Deemed to be University), Mullana-Ambala 133207, India
Interests: phytochemicals; apoptosis; chemoprevention; nano-formulation
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nearly 60% of human cells’ transcriptome is made up of non-coding RNAs (ncRNAs), which play a role in controlling cellular pathways and functions that are related to both health and illness. Important cellular programs are often controlled by a highly complicated regulatory network involving multiple interacting ncRNAs. The disruption of these processes can significantly alter the cell’s fate, which aids in the development of cancer. Recent developments in next-generation sequencing (NGS) and single-cell sequencing technologies have further verified this notion. Accumulating evidence highlights the interaction between traditional ncRNAs, such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), through binding sites. In competitive endogenous RNA (ceRNA) mechanisms, lncRNAs absorb miRNAs, suppressing their regulatory effects on mRNAs. Additionally, other ncRNA species, including vault RNAs (vtRNAs), PIWI-interacting RNAs (piRNAs), and small nucleolar RNAs (snoRNAs), have been linked to controlling gene expression. miRNAs and piRNAs, which are derived from snoRNAs, function in similar regulatory pathways.

This Special Issue welcomes original research, reviews, and systematic reviews that focus on recent advances related to the function, mechanisms, method of interactions, clinical applications, biomarker potential, and therapeutic implications of ncRNA in cancer.

Dr. Vikas Yadav
Dr. Hardeep Singh Tuli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Genes is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • non-coding RNA
  • miRNA
  • lncRNA
  • circRNA
  • piRNA
  • snoRNA
  • cancer biomarker
  • cancer therapy

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

19 pages, 2996 KiB  
Review
MYOSLID: A Critical Modulator of Cancer Hallmarks
by Kanupriya Medhi, Sagarika Mukherjee, Aastha Dagar, Ashutosh Kumar Tiwari, Sia Daffara, Sanjana Bana, Vivek Uttam, Md Rizwan Ansari, Vikas Yadav, Hardeep Singh Tuli and Aklank Jain
Genes 2025, 16(3), 341; https://doi.org/10.3390/genes16030341 - 14 Mar 2025
Viewed by 992
Abstract
Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID [...] Read more.
Despite being the leading cause of death worldwide, cancer still lacks precise biomarkers for effective targeting, limiting efforts to reduce mortality rates. This review explores the role and clinical significance of a newly identified long non-coding RNA, MYOSLID, in cancer progression. MYOSLID has emerged as a critical modulator in cancer progression by influencing key hallmarks such as proliferation, immune evasion, metastasis, and metabolic reprogramming. It promotes tumor cell growth by stabilizing hypoxia-inducible factor 1 and acting as a competing endogenous RNA (ceRNA) to sequester tumor-suppressive microRNAs like miR-29c-3p, thereby enhancing oncogene expression. It facilitates immune evasion by upregulating PD-L1, suppressing T cell activation, and modulating necroptosis pathways involving RIPK1 and RIPK3. Additionally, MYOSLID drives metastasis by regulating epithelial–mesenchymal transition markers such as LAMB3 and Slug while promoting RAB13-mediated cytoskeletal remodeling and enhancing cancer cell invasion. We have obtained the expression of MYOSLID from TCGA and the ENCORI database. The expression of colorectal adenocarcinoma (COAD) and head and neck squamous cell carcinoma (HNSCC) is associated with poor prognosis and lower survival rate. Given its significant potential as a diagnostic biomarker and therapeutic target, further research is required to elucidate its precise molecular mechanisms and therapeutic applications in cancer treatment. Full article
(This article belongs to the Special Issue Multifaceted Implications of Non-Coding RNAs in Cancer: From Biomarker Discovery to Therapeutic Target)
►▼ Show Figures

Figure 1

33 pages, 2346 KiB  
Review
Landscape of Noncoding RNA in the Hypoxic Tumor Microenvironment
by Lianfeng Gong, Chuanxin Zou, Haixia Zhang, Fei Yang, Gui Qi and Zhaowu Ma
Genes 2025, 16(2), 140; https://doi.org/10.3390/genes16020140 - 24 Jan 2025
Viewed by 880
Abstract
Amidst the prevalent and notable characteristic of a hypoxic microenvironment present in the majority of solid tumors, a burgeoning number of studies have revealed the significance of noncoding RNAs (ncRNAs) in hypoxic tumor regions. The transcriptome of cancers is highly heterogeneous, with noncoding [...] Read more.
Amidst the prevalent and notable characteristic of a hypoxic microenvironment present in the majority of solid tumors, a burgeoning number of studies have revealed the significance of noncoding RNAs (ncRNAs) in hypoxic tumor regions. The transcriptome of cancers is highly heterogeneous, with noncoding transcripts playing crucial roles. Long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) are two distinctive classes of ncRNA that are garnering increasing attention. Biologically, they possess intriguing properties and possess significant regulatory functions. Clinically, they present as promising biomarkers and therapeutic targets. Additionally, recent research has evaluated the clinical applications of these ncRNAs in RNA-based treatments and noninvasive liquid biopsies. This review provides a comprehensive summary of recent studies on lncRNAs and circRNAs within the hypoxic tumor microenvironment. Furthermore, the clinical significance of lncRNAs and circRNAs in cancer diagnosis and treatment is emphasized, which could pave the way for the development of effective targeted therapies. Full article
(This article belongs to the Special Issue Multifaceted Implications of Non-Coding RNAs in Cancer: From Biomarker Discovery to Therapeutic Target)
►▼ Show Figures

Graphical abstract

Other

Jump to: Review

11 pages, 691 KiB  
Brief Report
Exploring the Prognostic Potential of circSCORE in Patients with Relapsed/Refractory Mantle Cell Lymphoma
by Ruth Salim, Christian Winther Eskelund, Mats Jerkeman, Arne Kolstad, Riikka Räty, Christian Geisler, Martin Hutchings, Carsten Utoft Niemann, Lone Bredo Pedersen, Jonas Raaschou-Pedersen, Eileen Wedge, Juan Luis García-Rodríguez, Lasse Sommer Kristensen, Mette Dahl and Kirsten Grønbæk
Genes 2025, 16(6), 634; https://doi.org/10.3390/genes16060634 - 25 May 2025
Abstract
Background and Objectives: Mantle cell lymphoma (MCL) is a highly heterogenous disease, but an optimal prognostic biomarker in relapsed/refractory (R/R) MCL has not yet been established. The circular RNA-based risk score, circSCORE, was recently proposed as a promising prognosticator in newly diagnosed, [...] Read more.
Background and Objectives: Mantle cell lymphoma (MCL) is a highly heterogenous disease, but an optimal prognostic biomarker in relapsed/refractory (R/R) MCL has not yet been established. The circular RNA-based risk score, circSCORE, was recently proposed as a promising prognosticator in newly diagnosed, younger patients with MCL. This study explores the prognostic potential of circSCORE in R/R MCL in both nodal (lymph node (LN)) and non-nodal tissues (bone marrow (BM)) and peripheral blood (PB)). Materials and Methods: RNA was extracted from 65 relapse samples consisting of first-relapse LN samples (n = 20) from patients who previously underwent first-line treatment in the MCL2 and MCL3 trials, and either BM (n = 34) or PB (n = 11) samples obtained from patients with R/R MCL included in the MCL6 trial, taken at trial baseline. Kaplan–Meier estimates, and Cox regressions were used to evaluate the association between circSCORE risk groups (high versus low) and outcomes. Results: Survival analyses showed significantly inferior outcomes for patients with high-risk circSCORE compared to low-risk score for both progression-free survival (PFS) (hazard ratio (HR) 1.99, p-value 0.0407) and overall survival (OS) (HR 2.29, p-value 0.0192) in the total cohort. The same tendencies were displayed when exploring the non-nodal samples only. Furthermore, circSCORE retained prognostic impact for PFS, but not OS, when adjusted for Ki67, MIPI, and TP53 mutation status. Conclusions: The circRNA-based risk score, circSCORE, displayed prognostic potential in R/R MCL along with promising application in non-nodal tissues, indicating that circSCORE, if further validated, might serve as an easily obtainable biomarker in R/R MCL. Full article
(This article belongs to the Special Issue Multifaceted Implications of Non-Coding RNAs in Cancer: From Biomarker Discovery to Therapeutic Target)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop